Table 1 Patient demographics and clinical characteristics at baseline by tocilizumab and abatacept initiators
Characteristic | Unmatched | Matched | ||||
|---|---|---|---|---|---|---|
TCZ Initiators | ABA Initiators | Standardized differencea | TCZ Initiators | ABA Initiators | Standardized differencea | |
(n = 264) | (n = 663) | ABA – TCZ | (n = 264) | (n = 264) | ABA – TCZ | |
Female, n (%) | 197 (74.6) | 547 (82.9) | 0.2 | 197 (74.6) | 197 (74.6) | 0 |
Age, mean ± SD | 56.6 ± 12.4 | 57.3 ± 12.3 | 0.05 | 56.6 ± 12.4 | 56.6 ± 12.2 | –0.01 |
Race: White, n (%) | 201 (76.1) | 513 (77.4) | 0.03 | 201 (76.1) | 211 (79.9) | 0.09 |
Smoker, n (%) | ||||||
Never | 119 (45.1) | 305 (46.1) | 0.07 | 119 (45.1) | 115 (43.6) | 0.03 |
Previous | 90 (34.1) | 237 (35.8) | 90 (34.1) | 94 (35.6) | ||
Current | 55 (20.8) | 119 (18.0) | 55 (20.8) | 55 (20.8) | ||
Insuranceb, n (%) | ||||||
Private | 205 (77.6) | 516 (77.8) | 0.01 | 205 (77.6) | 193 (73.1) | –0.1 |
Medicaid | 12 (4.5) | 34 (5.1) | 0.03 | 12 (4.5) | 14 (5.3) | 0.03 |
Medicare | 96 (36.4) | 210 (31.7) | –0.1 | 96 (36.4) | 92 (34.8) | –0.03 |
None | 3 (1.1) | 10 (1.5) | 0.03 | 3 (1.1) | 6 (2.2) | 0.09 |
Duration of RA, mean ± SD | 10.7 ± 8.8 | 11.1 ± 9.3 | 0.03 | 10.7 ± 8.8 | 10.3 ± 10.0 | –0.03 |
RF/CCP seropositivity, n (%) | 127 (76.5) | 291 (74.1) | –0.06 | 127 (76.5) | 135 (73.7) | –0.06 |
History of comorbidities, n (%) | ||||||
Cardiovascular | 43 (16.3) | 88 (13.3) | –0.08 | 43 (16.3) | 41 (15.5) | –0.02 |
Malignancy | 14 (5.3) | 37 (5.6) | 0.01 | 14 (5.3) | 16 (6.1) | 0.03 |
Serious infection | 18 (6.8) | 67 (10.1) | 0.12 | 18 (6.8) | 23 (8.7) | 0.07 |
Diabetes | 26 (9.9) | 64 (9.7) | –0.01 | 26 (9.9) | 33 (12.5) | 0.08 |
mHAQ, mean ± SD | 0.7 ± 0.5 | 0.6 ± 0.5 | –0.16 | 0.7 ± 0.5 | 0.7 ± 0.5 | 0.02 |
CDAI, mean ± SD | 27.8 ± 12.1 | 27.1 ± 11.9 | –0.05 | 27.8 ± 12.1 | 28.1 ± 12.8 | 0.04 |
Tender joints, mean ± SD | 10.3 ± 7.6 | 10.0 ± 7.2 | –0.05 | 10.3 ± 7.6 | 10.4 ± 7.5 | 0.001 |
Swollen joints, mean ± SD | 7.0 ± 4.9 | 7.4 ± 5.6 | 0.08 | 7.0 ± 4.9 | 7.3 ± 5.8 | 0.05 |
Physician global, mean ± SD | 47.2 ± 20.4 | 43.8 ± 20.5 | –0.16 | 47.2 ± 20.4 | 47.7 ± 20.9 | 0.02 |
Patient global, mean ± SD | 57.0 ± 23.6 | 53.2 ± 23.9 | –0.16 | 57.0 ± 23.6 | 56.8 ± 23.3 | 0 |
Patient pain, mean ± SD | 58.6 ± 24.6 | 55.9 ± 25.4 | –0.1 | 58.6 ± 24.6 | 58.3 ± 25.5 | –0.01 |
ACR functional status, n (%) | ||||||
I | 55 (20.8) | 200 (30.2) | 55 (20.8) | 48 (18.2) | ||
II | 130 (49.2) | 306 (46.2) | 0.23 | 130 (49.2) | 138 (52.3) | 0.07 |
III/IV | 79 (29.0) | 157 (23.7) | 79 (29.9) | 78 (29.5) | ||
Prednisone use, n (%) | ||||||
None | 166 (63.4) | 415 (63.1) | 166 (63.4) | 168 (63.9) | ||
<10 mg | 53 (20.2) | 144 (21.9) | 0.04 | 53 (20.2) | 50 (18.8) | 0.03 |
≥10 mg | 43 (16.4) | 99 (15.1) | 43 (16.4) | 44 (16.5) | ||
Number of prior biologics used, n (%) | ||||||
1 | 99 (37.5) | 261 (39.4) | 0.12 | 99 (37.5) | 109 (41.3) | –0.08 |
2 | 94 (35.6) | 257 (38.8) | 165 (62.5) | 155 (58.7) | ||
3+ | 71 (26.9) | 145 (21.8) | ||||
Concomitant use of cDMARD, n (%) | 180 (68.2) | 456 (68.8) | 0.01 | 180 (68.2) | 179 (67.8) | –0.01 |